STX100 / SyntheX Labs - LARVOL DELTA

A novel immunogenic cell death that exploits the cancer-specific overexpression of Rad51 (AACR 2024) - "Rather, the elevated abundance of Rad51 in cancer cells relative to healthy tissues underlies the selective cytotoxicity resulting from an acute calcium surge upon STX100-mediated target engagement. The mechanism translates to in vivo models, where a single dose can achieve sustained survival when administered locally as a mono-therapy or in combination with an immune checkpoint blockade agent."

Immunogenic cell death • Oncology • RAD51